EUVIMEDEUVIMED entdecken
Open Access

Targeting APOBECs in cancer: It’s about timing

Aaron N Hata, Mani Larijani

Cancer Cell · 2024-04 · 42 (4) · 497-501

DOI: 10.1016/j.ccell.2024.03.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2024-04. Verfasst von Aaron N Hata und 1 weiteren Autor:innen. Beteiligte Einrichtung: Massachusetts General Hospital Cancer Center, Boston, MA, USA; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Bos…. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Leukemia and Lymphoma Society of Canada, Ludwig Center at Harvard.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

APOBEC3 cytidine deaminases have emerged as key drivers of mutagenesis in a wide spectrum of tumor types and are now appreciated to play a causal role in driving tumor evolution and drug resistance. As efforts to develop APOBEC3 inhibitors progress, understanding the timing and consequences of APOBEC3-mediated mutagenesis in distinct clinical contexts will be critical for guiding the development of anti-cancer therapeutic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsHumansMutagenesisCytidine DeaminaseAPOBEC Deaminases

Substanzen

Cytidine DeaminaseAPOBEC Deaminases

Autor:innen und Institutionen

  • Massachusetts General Hospital Cancer Center, Boston, MA, USA; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. Electronic address: ahata@mgh.harvard.edu.
  • Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada. Electronic address: mani_larijani@sfu.ca.

Förderung

  • NCI NIH HHS
  • Leukemia and Lymphoma Society of Canada
  • Ludwig Center at Harvard
  • NIH
  • Lotte and John Hecht Memorial Foundation

Zitieren

APA

Hata, A. N., & Larijani, M. (2024). Targeting APOBECs in cancer: It’s about timing. Cancer Cell, 42(4), 497-501. https://doi.org/10.1016/j.ccell.2024.03.010

Vancouver

Hata AN, Larijani M. Targeting APOBECs in cancer: It’s about timing. Cancer Cell. 2024;42(4):497-501. doi:10.1016/j.ccell.2024.03.010

BibTeX
@article{Hata2024,
  author = {Hata, Aaron N and Larijani, Mani},
  title = {Targeting APOBECs in cancer: It’s about timing},
  journal = {Cancer Cell},
  year = {2024},
  volume = {42},
  number = {4},
  pages = {497--501},
  doi = {10.1016/j.ccell.2024.03.010}
}
Kostenlos starten →